Skip NavigationSkip to Content
Return Return to Search Results

Bridging communities in the field of nanomedicine

  1. Author:
    Halamoda-Kenzaoui, Blanka
    Baconnier, Simon
    Bastogne, Thierry
    Bazile, Didier
    Boisseau, Patrick
    Borchard, Gerrit
    Borgos, Sven Even
    Calzolai, Luigi
    Cederbrant, Karin
    Di Felice, Gabriella
    Di Francesco, Tiziana
    Dobrovolskaia,Marina
    Gaspar, Rogério
    Gracia, Belén
    Hackley, Vincent A
    Leyens, Lada
    Liptrott, Neill
    Park, Margriet
    Patri, Anil
    Roebben, Gert
    Roesslein, Matthias
    Thürmer, René
    Urbán, Patricia
    Zuang, Valérie
    Bremer-Hoffmann, Susanne

  2. Author Address

    European Commission Joint Research Centre (JRC), Ispra, Italy., Universit 233; Grenoble Alpes, CEA LETI MlNATEC Campus, Grenoble, France., Universit 233; de Lorraine, CNRS, CRAN, INRIA BIGS, Nancy, France., CMC External Innovation, Sanofi, Gentilly, France., Universit 233; de Gen 232;ve, Ecole de Pharmacie Gen 232;ve-Lausanne, Gen 232;ve, Switzerland., SINTEF Industry, Trondheim, Norway., Swedish Toxicology Sciences Research Center (Swetox), S 246;dert 228;lje, Sweden., National Center for Drug Research and Evaluation, Istituto Superiore di Sanit 224;, Roma, Italy., Nanotechnology Characterization Laboratory (NCL), Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Sponsored By the National Cancer Institute, Frederick, USA., Faculty of Pharmacy and Institute for Bioengineering and Biosciences of the University of Lisbon, Lisboa Portugal., Department of Medicines for Human Use, Agencia Espa 241;ola de Medicamentos y Productos Sanitarios, Madrid, Spain., National Institute of Standards and Technology (NIST), Materials Measurement Science Division, Gaithersburg, USA., Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland., Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom., RIVM- National Institute for Public Health and the Environment, Bilthoven, Netherlands., U.S. Food & Drug Administration (FDA), Nanotechnology Core Facility, Jefferson, USA., European Commission Joint Research Centre (JRC), Geel, Belgium., Empa - Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, Switzerland., BfArM - Federal Institute for Drugs and Medical Devices, Bonn, Germany., European Commission Joint Research Centre (JRC), Ispra, Italy. Electronic address: susanne.bremer-hoffmann@ec.europa.eu.,
    1. Year: 2019
    2. Date: Aug
    3. Epub Date: 2019 04 30
  2. Journal: Regulatory toxicology and pharmacology : RTP
    1. 106
    2. Pages: 187-196
  4. Type of Article: Article
  5. ISSN: 0273-2300
  1. Abstract:

    An early dialogue between nanomedicine developers and regulatory authorities are of utmost importance to anticipate quality and safety requirements for these innovative health products. In order to stimulate interactions between the various communities involved in a translation of nanomedicines to clinical applications, the European Commission's Joint Research Centre hosted a workshop titled "Bridging communities in the Field of Nanomedicine" in Ispra/Italy on the 27th -28th September 2017. Experts from regulatory bodies, research institutions and industry came together to discuss the next generation of nanomedicines and their needs to obtain regulatory approval. The workshop participants came up with recommendations highlighting methodological gaps that should be addressed in ongoing Horizon 2020 projects addressing the regulatory science of nanomedicines. In addition, individual opinions of experts relevant to progress of the regulatory science in the field of nanomedicine were summarised in the format of a survey. Copyright © 2019. Published by Elsevier Inc.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.yrtph.2019.04.011
  3. PMID: 31051191
  4. View record in Web of Science®
  5. WOS: 000513219700018
  6. PII : S0273-2300(19)30110-2

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel